# Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

> **NCT00975637** · PHASE2 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 198 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** 70 mg SC
- **DRUG:** 210 mg SC
- **DRUG:** 140 mg SC
- **DRUG:** 280 mg SC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00975637
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-09
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975637, "Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00975637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*